ABSI:NSD-Absci Corporation Common Stock (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 10.97

Change

-1.00 (-8.35)%

Market Cap

USD 0.97B

Volume

0.52M

Avg Analyst Target

USD 26.67 (+143.09%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington. Address: 18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683

Company Website : http://www.absci.com

Address : 18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683

Employees : 169

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 31.53

Short Ratio : 5.51

52 Week Low : 10.32

Shorted Shares : 1,626,508

200 Day Moving Average : 21.21

Shorted Shares Previous Month : 693,619

50 Day Moving Average : 20.50

Shares Held By Insiders : 17.05%

Short Percentage : 2.00%

Shares Held by Institutions : 21.37%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.72 (-1.56%)

 USD173.59B 50.81 42.25
BNTX BioNTech SE

-20.17 (-5.62%)

 USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

-10.99 (-1.69%)

 USD69.72B 11.77 9.06
VRTX Vertex Pharmaceuticals Incorpo..

-2.63 (-1.40%)

 USD48.85B 24.83 16.63
BGNE BeiGene Ltd

-4.64 (-1.15%)

 USD42.80B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
SGEN Seagen Inc

+2.85 (+1.82%)

 USD28.42B 48.74 39.11
GMAB Genmab A/S

-0.18 (-0.42%)

 USD28.19B 71.63 8.17
RPRX Royalty Pharma plc

-1.67 (-4.34%)

 USD23.38B 31.17 12.50
ALNY Alnylam Pharmaceuticals Inc

-6.88 (-3.61%)

 USD21.80B N/A N/A

ETFs Containing ABSI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.97B 72% C- 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -88.00 95% A 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 21.81% 91% A- 90% A-
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio -4.63% 92% A- 93% A
Technical Ratios  
Short Ratio 5.51 44% F 30% F
Short Percent 3.83% 62% D- 42% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.